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Abstract
Background: Methicillin-resistant S. aureus (MRSA) has been endemic in Hospital Universitari de Bellvitge,
Barcelona, since 1990. During the 1990-95 period the Iberian clone (ST-247; SCCmec-I) was dominant. Isolates of
clonal complex 5 (ST-125; SCCmec-IV) gradually replaced the Iberian clone from 1996 to 2003. A new multiresistant
MRSA phenotype showing rifampicin resistance emerged in 2004 and rapidly increased from 25% in 2004 to 45%
in 2006. The aims of this study were i) the molecular characterisation of rifampicin resistant MRSA isolates, ii) the
study of the rifampicin resistance expression by disk diffusion, microdilution and E-test, and iii) the analysis of the
rpoB gene mutations involved in rifampicin resistance.
Results: A sample of representative 108 rifampicin-resistant MRSA isolates belonged to a single PFGE genotype,
ST-228, SCCmec type I and spa type t041. Of 108 isolates, 104 (96%) had a low-level rifampicin resistance (MICs,
2 to 4 mg/L) and 4 a high-level rifampicin resistance (MICs, 128 - ≥ 256 mg/L). Disk diffusion and E-test methods
failed to identify a low-level rifampicin resistance in 20 and 12 isolates, respectively. A low-level rifampicin
resistance was associated with amino acid substitution 481His/Asn in the beta-subunit of RNA polymerase.
Isolates with a high-level rifampicin resistance carried additional mutations in the rpoB gene.
Conclusions: The emergence of MRSA clone ST228-SCCmecI, related to the Southern Germany clone, involved a
therapeutical challenge for treating serious MRSA infections. Decreased susceptibility to rifampicin in MRSA strains
of ST228-SCCmecI was associated with one or two specific mutations in the rpoB gene. One fifth of isolates with
low-level rifampicin-resistance were missed by the diffusion methods.
Background
Methicillin resistant Staphylococcus aureus (MRSA) is
an important pathogen in Spanish hospitals. The per-
centage of patients infected or colonised by MRSA
among patients with nosocomial S. aureus has been esti-
mated between 20.2% and 30.5% in nation-wide multi-
center studies [1,2].
In the Hospital Universitari de Bellvitge MRSA has
been endemic since 1990. The majority of strains iso-
lated during the 1990-95 period belonged to the multi-
resistant Iberian clone. By multilocus sequence typing
(MLST) the Iberian clone showed an allelic profile or
sequence type (ST) 247, carrying the staphylococcal cas-
sette chromosome mec (SCCmec) type I [3]. Isolates of
the Iberian clone exhibited resistance against almost all
antibiotics available for MRSA therapy including clinda-
mycin, erythromycin, gentamicin, tobramycin, tetracy-
cline, ciprofloxacin and rifampicin. From 1996 to 2003,
the Iberian clone was gradually replaced by isolates of
Clonal Complex 5 (ST125 and variants; SCCmec type
IV) related to the Paediatric clone (ST5; SCCmec type
IV) [4]. Unlike the Iberian clone, these strains showed
only consistent resistance to tobramycin and ciprofloxa-
cin combined with variable resistance to clindamycin
and/or erythromycin. Similar trends have been observed
in other hospitals in Spain and in other countries such
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as France, Germany, Belgium or Portugal, with involve-
ment of different clonal lineages [5-10]. MRSA isolates
resistant to clindamycin, erythromycin, gentamicin,
tobramycin, and ciprofloxacin were detected in 2004.
These isolates showed reduced susceptibility to rifampi-
cin (RIF-R), according to the Clinical and Laboratory
Standards Institute (CLSI) criteria [11]. This new pheno-
type of multiresistance differed from that of the Iberian
clone on the low level RIF-R and on the tetracycline
susceptibility. The frequency of the RIF-R MRSA iso-
lates rapidly increased from 2004 to 2006: 25% (59/237)
of all MRSA clinical isolates in 2004, 33% (67/206) in
2005, and 45% (116/256) in 2006. The percentage of
RIF-R MRSA decreased to 30% (111/378) in 2007 and
25% in 2008 (75/300).
Rifampicin cannot be used as a single agent to treat
MRSA infections because of the rapid selection of resis-
tant mutants [12,13]. However, combinations of rifampi-
cin with other anti-staphylococcal agents such as
quinolones [14] or fusidic acid [15] could prevent the
emergence of rifampicin resistance during therapy [16].
Rifampicin interacts specifically with the RNA polymer-
ase beta-subunit encoded by the gene rpoB [12]. Rifam-
picin resistance in S. aureus, as in other bacteria, is
associated with mutations in particular regions (cluster I
and II) of the gene rpoB [13,17].
The objectives of the present study were: i) to charac-
terise a collection of MRSA isolates expressing this new
multiresistant pattern, and to determine whether they
represented a novel genotype or they were the current
representatives of a previously detected clone, ii) to
determine the different levels of the rifampicin resis-
tance by disk diffusion, microdilution and E-test, and iii)
to analyse mutations in the rpoB gene related to rifam-
picin resistance.
Methods
Hospital setting
The Hospital Universitari de Bellvitge in Barcelona,
Spain, is a nearly 900-bed tertiary care teaching centre.
It is the reference hospital for a geographical area with a
population of approximately 1 million inhabitants. The
Hospital Universitari de Bellvitge in Barcelona provides
medical and surgical care for adult patients with an
average of 25,000 admissions per year. It has six inten-
sive care units with a total of 60 beds and an active
organ transplant program.
The control of MRSA in our institution is based on
the active screening of patients at risk and contact isola-
tion of infected or colonised patients. In spite of this
policy, the average rate of total MRSA among S. aureus
clinical isolates in our hospital was 24% for the 2004-
2007 period (minimum 23% in 2007 and maximum 26%
in 2006).
The present study has been approved by the Clinical
Research Ethics Committee of the Hospital Universitari
de Bellvitge.
Bacterial strains
Identification of S. aureus from clinical samples was per-
formed using conventional tests: catalase, latex aggluti-
nation (Microgen Staph, Microgen Bioproducts,
Camberley, England) and tube coagulase test (Staph-ase,
bioMérieux, Marcy l’Étoile, France).
Two hundred and forty-two non-duplicate isolates
resistant to clindamycin, erythromycin, gentamicin,
tobramycin, ciprofloxacin and resistant to rifampicin
(RIF-R) by the disk-diffusion or the microdilution
method were recovered in the Microbiology Department
of Hospital Universitari de Bellvitge from January 2004
to December 2006. These strains represented 34% of all
MRSA isolated between 2004 and 2006, and were iso-
lated from patients admitted to the different surgical,
medical and intensive care units in the hospital. One
hundred and eight isolates with rifampicin MIC ≥ 2 mg/
L were selected for the present study. The selection
included the first isolates available each year (33/59, 29/
67 and 46/116 isolates from 2004, 2005 and 2006,
respectively) from the different hospital wards affected.
The origin of the strains was from blood cultures or
catheter-related sites (n = 38), wound swabs (n = 28),
respiratory samples (n = 24), exudates (n = 12), nasal
swabs (n = 4) and sterile fluids (n = 2). Oral informed
consent was given by all patients before taking the clini-
cal specimen. The patient acquisition of MRSA infection
or colonisation was prospectively assessed. Five strains
with the same resistance pattern but fully susceptible to
rifampicin (RIF-S) (MIC 0.012 mg/L) were included in
this study. This RIF-S pattern represented about 4% of
all MRSA isolated between 2004 and 2006.
Antimicrobial susceptibility testing
Susceptibility testing of primary MRSA isolates is per-
formed routinely by the disk-diffusion method on Muel-
ler-Hinton 2 agar plates (MH2, bioMérieux) to the
following antibiotics: penicillin (10 units), oxacillin (1 μg),
cefoxitin (30 μg), erythromycin (15 μg), clindamycin
(2 μg), gentamycin (10 μg), tobramycin (10 μg), rifampicin
(5 μg), tetracycline (30 μg), trimethoprim-sulfamethoxa-
zole (1.25/23.75 μg), chloramphenicol (30 μg), ciprofloxa-
cin (5 μg), vancomycin (30 μg), teicoplanin (30 μg),
quinupristin/dalfopristin (15 μg) and linezolid (30 μg).
Disks are supplied by BD BBL (Sensi-Disc; Becton, Dickin-
son and Company, Sparks, MD 21152 USA). MICs of
rifampicin were determined in all strains selected for this
particular study (108 RIF-R and 5 RIF-S MRSA strains) by
microdilution (from 0.06 to 128 mg/L), following the
Clinical and Laboratory Standards Institute (CLSI)
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recommendations [11], and by E-test (AB biodisk, Solna,
Sweden). Isolates were interpreted as susceptible or resis-
tant, according to the CLSI criteria [11].
Detection of rifampicin resistance-associated mutations
An internal sequence of gene rpoB of 432 bp (nucleo-
tides 1216 to 1648) was amplified by PCR. This region
includes the rifampicin resistance-determining cluster I
(nucleotides 1384-1464, amino acid number 462-488)
and cluster II (nucleotides 1543-1590, amino acid num-
ber 515-530). The amplification was carried out in 5
RIF-S MRSA strains (rifampicin MICs, 0.012 mg/L), and
in a selection of 32 RIF-R strains showing different
levels of rifampicin resistance: MICs 2 mg/L, 21 strains;
MICs 4 mg/L, 7; MICs 128 mg/L, 2; and MICs ≥ 256
mg/L, 2. The oligonucleotide sequences used were rpoB-
for (5’-GTC GTT TAC GTT CTG TAG GTG-3’) and
rpoBrev (5’-TCA ACT TTA CGA TAT GGT GTT TC-
3’). Amplification was carried out in a 50 μl volume
containing 30 pmol of each primer, 200 μM deoxynu-
cleoside triphosphates (dATP, dCTP, dGTP and dTTP),
3 μl of a template DNA sample and 1 U of AmpliTaq
Gold DNA polymerase (Applied Biosystems, Madrid,
Spain). Thermal cycling reactions consisted of an initial
denaturation (9 min 30 at 94°C) followed by 35 cycles of
denaturation (30 s at 94°C), annealing (30 s at 62°C),
and extension (1 min at 72°C), with a final extension
(10 min at 72°C). The PCR product was purified (QIA-
quick PCR purification kit, Qiagen, Madrid, Spain) and
analysed by DNA sequencing. Cycle sequencing reac-
tions were made up in a final volume of 20 μl with ABI
BigDye Terminator v3.0 Ready Reaction Cycle Sequen-
cing kit, following manufacturer’s methodology (Applied
Biosystems). The nucleotide sequences obtained were
compared to the rpoB wild type sequence from S. aur-
eus subsp. aureus (GenBank accession number: X64172)
using the clustalw software http://www.ebi.ac.uk/tools/
clustalw/index.html.
Rifampicin-susceptible strains used as controls were:
ATCC29213 (rifampicin and methicillin susceptible
S. aureus) and ATCC700698 (rifampicin susceptible
MRSA). Two representatives of the Iberian clone
were used as rifampicin-resistant MRSA controls:
ATCCBAA44 [18,19] and PER88 [3,19].
Determination of spontaneous mutation frequency for
rifampicin resistance
The determination of spontaneous mutation frequency
for rifampicin resistance was aimed at identifying
whether the presence of a first mutation conferring low
level rifampicin resistance facilitated the acquisition of
supplementary mutations responsible for increasing
rifampicin MICs. The rifampicin mutation frequency
was calculated in reference strain ATCC700698 (MIC
0.006 mg/L) and in two RIF-R MRSA strains carrying
the low level resistance mutation His481/Asn (rifampi-
cin MICs of 1.5 and 2 mg/L, respectively). Bacterial
strains were cultured in a shaking incubator at 37°C in
Luria-Bertani (LB) broth (BD Diagnostics, Spain) until
the exponential growth phase. Each strain was plated on
the selective and non-selective LB agar plates and incu-
bated at 37°C. Rifampicin selecting concentrations were
2 and 20 mg/L for the reference strain, and 20 mg/L for
the RIF-R MRSA strains. In these experimental condi-
tions OD620 = 0.125 corresponded to 5 × 10
7 cfu/ml.
The equivalent to 107, 108 and 109 cfu were spread on
selective plates, and appropriated diluted samples were
plated on non-selective plates. After 24 h to 36 h, colo-
nies that grew on selective and non-selective plates were
counted and mutation frequencies were calculated.
Three independent experiments were performed to
ensure reproducibility.
Molecular typing
Pulsed Field Gel Electrophoresis
(PFGE) was performed after SmaI restriction of chromo-
somal DNA according to Chung et al. [20]. Pulses run
from 5 s to 15 s for 10 h for block 1, and from 15 s to
60 s for 13 h for block 2 [21]. Isolates with PFGE pat-
terns differing in four or less restriction fragments were
considered to be subtypes of a single genotype. Isolates
with differences in more than four fragments were
ascribed to distinct genotypes [22].
SCCmec typing
Molecular typing based on the amplification of the
mobile region mec was performed according to pre-
viously described procedures [23,24]. Control strains for
SCCmec typing were: ATCCBAA44 (SCCmec type I)
[18,19], ATCCBAA-41 (SCCmec type II) [19], ATCC-
BAA-39 (SCCmec type III) [19] and HGSA60 (SCCmec
type IV-A) [24].
Multilocus sequence typing
(MLST). Analysis of the seven housekeeping gene
sequences was performed according to previously
described procedures http://saureus.mlst.net/[25].
spa typing
The polymorphic region of protein A was studied
according to previously described procedures at http://
spa.ridom.de/[26]. The interest region was amplified
with primers spa-1113f (5’-TAA AGA CGA TCC TTC
GGT GAG C-3’) and spa-1514r (5’-CAG CAG TAG
TGC CGT TTG CTT-3’).
Results
Rifampicin resistance levels and associated
rpoB mutations
The majority (n = 104, 96%) of the 108 RIF-R MRSA
isolates, showed rifampicin MICs between 2 and 4 mg/
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L. Two isolates had rifampicin MICs of 128 mg/L and
the remaining two had MICs ≥ 256 mg/L. Correspond-
ing E-test and disk diffusion results are shown in table
1. On the basis of these results and following other
authors’ categorisation [13,17,27] the strains were classi-
fied into categories of rifampicin susceptible (MICs,
≤ 0.5 mg/L), low-level rifampicin resistance (MICs, 1 to
4 mg/L), and high-level rifampicin resistance (MICs, ≥
8 mg/L). Interestingly, 20 strains with rifampicin MICs
of 2 mg/L showed inhibition zones between 20 and
23 mm, borderline to the susceptible CLSI breakpoint
(inhibition zones ≥ 20 mm). The five RIF-S MRSA
isolates, with the same multi-resistance pattern, had
rifampicin MICs of 0.012 mg/L and inhibition zones
> 30 mm.
The mutations in the rifampicin resistance-determin-
ing region of rpoB gene were studied in 32 RIF-R and in
5 RIF-S MRSA strains. Results are shown in table 2. All
32 strains presented the mutational change 481His/Asn,
determined by a mutation in cluster I of rpoB gene, con-
ferring a low-level rifampicin resistance. The four iso-
lates with MIC≥ 128 mg/L had an additional amino acid
substitution: 468Gln/Lys (n = 1), 477Ala/Thr (n = 2) or
527Ile/Leu (n = 1), associated with a high level rifampi-
cin resistance. Mutational changes 468 and 477 were
determined by mutations located in cluster I and
substitution 527 was determined by a mutation located
in cluster II. RIF-S MRSA isolates, had no mutations
related to rifampicin resistance. All isolates, including
RIF-S isolates, and 3 (ATCC29213, ATCCBAA44, and
PER88) out of 4 control strains, presented a silent muta-
tion in amino acid 498 with the substitution Ala(GCG)
per Ala(GCT).
Frequency of spontaneous mutation for
rifampicin resistance
The rifampicin mutation frequency was calculated in
reference strain ATCC700698 (MIC, 0.006 mg/L) and in
two RIF-R MRSA strains carrying the low-level resistant
amino acid substitution 481His/Asn (rifampicin MICs,
1.5 and 2 mg/L, respectively). Rifampicin high level resis-
tant mutants occurred with frequencies of around 10-7 to
10-8 in the RIF-R MRSA strains after selection by rifam-
picin concentration of 20 mg/L. An identical mutational
ratio was found in the control strain ATCC700698 at
both selective concentrations (2 and 20 mg/L).
RIF-R MRSA genotypes by PFGE and epidemiology
All 108 RIF-R MRSA isolates belonged to the same gen-
otype by PFGE. This specific restriction pattern (B) was
unique, distinct from both the PFGE patterns obtained
for the multi-resistant RIF-S MRSA isolates (A) and
Table 1 MICs by microdilution and Etest and disk diffusion inhibition zones in 108 rifampicin resistant MRSA isolates
Microdilution MICs No. of strains E-test (range) MICs Inhibition zones by disk diffusion
No. of strains
≤ 16 mm 17-19 mm ≥ 20 mm
2 mg/L 97 0.75-2 mg/L 15 62 20
4 mg/L 7 3-4 mg/L 7 - -
128 mg/L 2 > 32 mg/L 2 - -
≥ 256 mg/L 2 > 32 mg/L 2 - -
Table 2 Level of rifampicin resistance and mutations found in the rpoB gene of MRSA isolates and control strains
Genotype
(ST/SCCmec/PFGE)
Rifampicin MICs
(mg/L)
Number of isolates Nucleotide mutation Amino acid substitution
ST228/IV-A/A 0.012 5 None
ST228/I/B 2-4 28 CAT®AAT 481His®Asn
ST228/I/B 128 2 CAT®AAT
GCT®ACT
481His®Asn
477Ala®Thr
ST228/I/B ≥ 256 1 CAT®AAT
CAA®AAA
481His®Asn
468Gln®Lys
ST228/I/B ≥ 256 1 CAT®AAT
ATT®CTT
481His®Asn
527Ile®Leu
ST247/I
PER88
(Iberian clone)
≥ 256 1 CAT®AAT
TCA®TTA
481His®Asn
529Ser®Leu
ST247/I
ATCCBAA44
(Iberian clone)
2 1 CAT®AAT 481His®Asn
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from representatives of the Iberian clone (figure 1). The
RIF-R MRSA isolates were classified into eight subtypes
(B-1 to B-8) with pattern B-1 being the most frequent
(49%; 53/108 strains), followed by subtype B-2 (34%; 37/
108). Subtype B-1 was dominant during 2004 represent-
ing 76% (25/33) of studied isolates, then decreased dur-
ing 2005 (24%; 7/29) and rose in 2006 to 48% (22/46).
Subtype B-2 represented 52% (15/29) in 2005, and 48%
(22/46) in 2006. No correlation could be established
between rifampicin resistance levels and PFGE subtypes.
This RIF-R clone was not restricted to a specific hospital
ward. Isolates were obtained from patients admitted to
intensive care, medical and surgical units. Almost all
patients included in this study (101/108, 93%) acquired
the MRSA in our hospital. Seven patients acquired the
RIF-R MRSA infection or colonisation in a prior admis-
sion to another hospital.
SCCmec typing, MLST and spa typing
SCCmec typing was carried out in the 32 strains where
rpoB mutations were characterised. This selection
included representatives of the eight PFGE B subtypes.
Also RIF-S MRSA strains were analysed for SCCmec
type. All 32 RIF-R MRSA strains carried a SCCmec type
I. The 5 RIF-S of PFGE pattern A carried a SCCmec
type IV-A. Interestingly, all strains belonged to a com-
mon MLST type: ST228, defined by alleles arcc 1, aroe
4, glpf 1, gmk 4, pta 12, tpi 24, and yqi 29 (table 3).
In parallel, a selection of 18 RIF-R MRSA strains and
the 5 RIF-S MRSA were further genotyped by spa typ-
ing. All RIF-R strains belonged to spa-type t041. Among
the RIF-S MRSA strains, three belonged to spa-type
t2222 and two showed novel spa-types (r26-r30-r17-r13-
r17-r13-r17-r12-r17-r12 and r26-r30-r17-r20-r17-r12-
r17-r12-r17-r16).
Discussion
The multi-resistant nature of most MRSA clones found
in hospitals represents a therapeutical challenge for
treating serious MRSA infections. The burden that the
Iberian clone posed in Spanish hospitals in the early
90 s [3,28], shifted to other clones susceptible to more
Figure 1 PFGE subtypes of MRSA strains with decreased susceptibility to rifampicin (RIF-R), “B-1” to “B-8”. PFGE pattern “A” corresponds
to a rifampicin susceptible MRSA isolate (RIF-S). PFGE patterns of controls are shown: Iberian clone (IC) representatives (PER88 and ATCCBAA44),
ATCC2913 and ATCC70069.
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antibiotics, which have been dominant in recent years
[8,29]. In this paper, we described the emergence and
spread of a MRSA clone resistant to clindamycin, ery-
thromycin, gentamicin, tobramycin, ciprofloxacin and
rifampicin which has reduced substantially the number
of effective antibiotics for treatment of serious MRSA
infections.
Rifampicin is an antibiotic of substantial interest in
the rise of MRSA infections, but cannot be used as a
single agent to treat such infections because rapid emer-
gence of resistance can occur, even during therapy
[16,30,31]. Although the role of rifampicin as adjunctive
therapy is controversial [31], the combined therapy
seems beneficial as long as the bacteria exhibit suscept-
ibility to the antibiotics combined [30]. The distinctive
phenotypic feature in the particular clone of ST-228
described here was the borderline resistance to rifampi-
cin that could be missed by some methods of antimicro-
bial susceptibility testing (i.e. disk diffusion or E-test).
Hence our interest in studying whether this low-level
RIF-R was an adaptive phenomenon or to the contrary,
known rpoB mutations underlay such phenotype.
Almost all isolates belonging to this multi-resistant
MRSA clone (104/108) showed a low-level rifampicin
resistance (MICs, 1 to 4 mg/L) and carried the amino
acid substitution 481His/Asn in the RNA polymerase.
Only 4 isolates showed additional substitutions known
to be involved in a high-level rifampicin resistance: two
isolates (MICs, 128 mg/L) carried mutational change
477Ala/Thr, and one isolate (MIC, ≥ 256 mg/L)
468Gln/Lys [13,17,27,32]. The fourth isolate (MIC,
≥ 256 mg/L) showed substitution 527Ile/Leu, the only
one which mutation was found in the rifampicin resis-
tance-determining cluster II, described recently among
Japanese MRSA isolates [32]. It is noteworthy that
20 isolates (19%) of the RIF-R isolates, carrying rpoB
mutation resulting in amino acid substitution in position
481, were detected as rifampicin susceptible by the disk-
diffusion test. However, the inhibition zones of these
strains were between 20 and 23 mm, closer to the
susceptibility breakpoint established by CLSI (suscept-
ibility ≥ 20 mm) than inhibition zones among RIF-S
MRSA isolates that were usually ≥ 30 mm. Therefore, if
screening for rifampicin resistance is made only by disk
diffusion, special attention needs to be paid to strains
borderline to the CLSI susceptibility breakpoint to avoid
reporting false susceptibility results. MICs by E-test
failed to detect rifampicin resistance following CLSI
guidelines [11] in a group of 12 strains (MICs, 0.75-1
mg/L). These isolates showed MICs by microdilution of
2 mg/L and carried the rpoB mutation responsible for
amino acid substitution in position 481. Thus, and
according to other authors, it would be advisable to
apply ≤ 0.5 and ≥ 8 mg/L as new breakpoints to classify
rifampicin susceptibility or resistance in S. aureus clini-
cal isolates [13,17].
High-level rifampicin resistance could be attributable
to double mutations within rpoB, as previously described
[27]. We did not find in this particular clone that the
presence of a prior mutational change (481His/Asn)
increased the frequency of acquisition of additional
mutations responsible for a higher level of rifampicin
resistance, when compared to a reference strain.
The multi-resistance pattern exhibited by the Iberian
clone, dominant lineage in our hospital during the 90’s,
also included resistance to tetracycline. The new RIF-R
MRSA isolates were resistant to clindamycin, erythro-
mycin, gentamicin, tobramycin, ciprofloxacin and sus-
ceptible to tetracycline. However, molecular typing
showed that the Iberian clone and the new RIF-R
MRSA clone had different genetic backgrounds repre-
sented by ST-247 and ST-228, respectively, with only a
single locus in common. Although both clones carried a
SCCmec element type I, PFGE patterns and spa-types
were clearly different.
All strains with the multi-resistant phenotype
described in this work, showing resistance or decreased
susceptibility to rifampicin, belonged to ST-228, carried
a SCCmec element type I and were spa-type t041. This
clone seems to be related to the Southern Germany
clone (ST-228, SCCmec type I, spa-type t001 or spa-
type t041) reported in Germany in 1997-98 [21,33]. In
the same period, strains of ST-228 and SCCmec type I
were reported at several hospitals located in seven Ita-
lian cities [34], although these isolates also showed resis-
tance to multiple antibiotics, rifampicin resistance was
not stated. Recently, strains of ST-228 have spread epi-
demically in Finland in 2002-2004 and in Hungary in
Table 3 Molecular features and resistance patterns of multi-resistant MRSA isolates resistant and susceptible to
rifampicin
MLST
(ST)
SCCmec type PFGE spa-type Resistance pattern1
ST 228 I B t041 OXA, ERY, CLI, GEN, TOB, RIF, CIP
ST 228 IVA A t2222 or novel OXA, ERY, CLI, GEN, TOB, CIP
ST 247 I Iberian clone
(ATCCBAA44; PER88)
t051 OXA, ERY, CLI, GEN, TOB, RIF, CIP, TET
(1OXA, oxacillin; ERY, erythromycin; CLI, clindamycin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; RIF, rifampicin)
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2003-2004 [35,36]. Also, ST-228 has been reported in
other European countries: Belgium, Slovenia or Switzer-
land [37]. The first isolate ST-228, SCCmec type I was
isolated in our hospital in September 2003, from a
patient admitted to the ICU. However, it was not until
March 2004 that this clone spread epidemically in our
hospital and currently represents one third of all clinical
MRSA isolates in our institution. Strains belonging to
ST-228 have been reported in other hospitals in Spain
since 1996 [9,29,38]. However, none of these reports
(from Spain or other countries) analysed the decreased
susceptibility to rifampicin among representative strains
of ST-228. During the 2004-2007 period, we did not
find significant changes in the rifampin consumption in
our institution, which was on average 0.5 DDD/100
patients-days for intravenous and 1.0 DDD/100 patients-
days for oral administration.
A set of 5 strains resistant to clindamycin, erythromy-
cin, gentamicin, tobramycin, ciprofloxacin, but fully sus-
ceptible to rifampicin with MICs of 0.012 mg/L were
included in this study. On average, this RIF-S pattern
represented 4% of all MRSA isolated between 2004 and
2006, however this resistance phenotype can be traced
back to 1999 in our hospital. The RIF-S isolates were
classified as ST-228, the same as the RIF-R MRSA. Iso-
lates of ST-228 (MLST, arcc 1, aroe 4, glpf 1, gmk 4, pta
12, tpi 24, and yqi 29) belong to the Clonal Complex 5,
as well as isolates of ST-125 (MLST, arcc 1, aroe 4, glpf
1, gmk 4, pta 12, tpi 1, and yqi 54) which was the domi-
nant MRSA clone in Hospital Universitari de Bellvitge
from 1996 to 2003. Consequently, an alternative hypoth-
esis to explain the emergence of multiresistant clone
ST-228, SCCmec type I would be the SCCmec type I
transfer from ST-247 to the ST-125 background, with
an intermediate stage where RIF-S isolates could be
found belonging to ST-228.
Conclusion
Our study describes the hospitalary spread of an MRSA
clone (ST-228, SCCmec-I, spa-t041), related to the
Southern-Germany clone (ST-228, SCCmec type I, spa-
type t001 or spa-type t041) [21,33]. In this particular
case, the studied strains were resistant to many more
antibiotics than any previous MRSA clone spread in our
institution, with the exception of the Iberian clone. In
addition, the study of the rpoB mutations demonstrated
that rifampin was not a suitable option for treatment of
infections caused by this clone.
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